Program
Autologous Anti-PRAME TCR-expressing T-cells OPB-201
Its studies are mostly in Endometrial Neoplasms, led by Outpace Bio.
Furthest: phase 1, since Jun 17, 20261 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Outpace Bio | 11 open or running | phase 1since Jun 17, 2026 | Jun 17, 2026 | Jun 2030phase 1 · NCT07664735 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07664735 · 30 planned · United States
Ahead
- Jun 2030Primary completion: phase 1 study in Endometrial NeoplasmsNCT07664735
TargetBeta
PRAME →read by rule
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule
Other programs on PRAME
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| anzutresgene autoleucelrule | immatics-us-inc | phase 3 | 3 |
| PRAME mRNA Vaccine mRNA-4203rule | immatics-us-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07664735Endometrial Neoplasms · United States | 1 | Recruiting | Jun 2030 | 30 |
How it is read
Names in the registry
- “OPB-201”, 1 entry
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.